Citigroup
AMLX icon

Citigroup’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citigroup’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71,700
Closed -$1.06M – 5625
2023
Q4 		$1.06M Buy
71,700
+13,500
+23% +$207K ﹤0.01% 2780
2023
Q3 		$1.07M Sell
58,200
-2,500
-4% -$52.9K ﹤0.01% 2454
2023
Q2 		$1.31M Buy
60,700
+30,700
+102% +$829K ﹤0.01% 2617
2023
Q1 		$880K Sell
30,000
-23,100
-44% -$802K ﹤0.01% 2663
2022
Q4 		$1.96M Sell
53,100
-65,800
-55% -$2.34M ﹤0.01% 2052
2022
Q3 		$3.35M Buy
+118,900
New +$2.97M ﹤0.01% 1785

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Citigroup's AMLX Position: Q1 2026 in Review

Citigroup reduced its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q1 2026, selling an estimated $87.9K and leaving 31,782 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #3624.

Citigroup first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $5.71M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Citigroup held 31,782 shares of Amylyx Pharmaceuticals worth $442K as of Q1 2026.
  • Citigroup sold 6,250 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $87.9K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3624 holding.
  • Citigroup first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Citigroup's Amylyx Pharmaceuticals position peaked at $5.71M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.